Impact of immunosuppressive treatment and type of SARS-CoV-2 vaccine on antibody levels after three vaccinations in patients with chronic kidney disease or kidney replacement therapy.
Bouwmans, Pim; Messchendorp, A Lianne; Imhof, Céline; Sanders, Jan-Stephan F; Hilbrands, Luuk B; Reinders, Marlies E J; Vart, Priya; Bemelman, Frederike J; Abrahams, Alferso C; van den Dorpel, René M A; Ten Dam, Marc A G J; de Vries, Aiko P J; Rispens, Theo; Steenhuis, Maurice; Gansevoort, Ron T; Hemmelder, Marc H
Citations
Altmetric:
Series / Report no.
Open Access
Type
Article
Language
en
Date
2022-11-24
Research Projects
Organizational Units
Journal Issue
Title
Impact of immunosuppressive treatment and type of SARS-CoV-2 vaccine on antibody levels after three vaccinations in patients with chronic kidney disease or kidney replacement therapy.
Translated Title
Published in
Clin Kidney J 2023;16(3):528-540
Abstract
Control subjects (n = 186), patients with CKD G4/5 (n = 400), dialysis patients (n = 480) and kidney transplant recipients (KTR) (n = 2468) were vaccinated with either mRNA-1273 (Moderna), BNT162b2 (Pfizer-BioNTech) or AZD1222 (Oxford/AstraZeneca) in the Dutch SARS-CoV-2 vaccination programme. Third vaccination data were available in a subgroup of patients (n = 1829). Blood samples and questionnaires were obtained 1 month after the second and third vaccination. Primary endpoint was the antibody level in relation to immunosuppressive treatment and type of vaccine. Secondary endpoint was occurrence of adverse events after vaccination.